Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

H.C. Wainwright analyst Arthur He raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating ...

Finding an effective, safe medication to control itch is essential to maximize patient comfort. Because Zenrelia does not require a loading dose and is administered once daily, Zenrelia may help impro ...

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in ...

An analyst tracking the stock made a drastic change to his price target. The latest biotech stock to explode in price, Nektar ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...

The licensing deal for BAFF/APRIL inhibitor telitacicept, which also includes regulatory and commercial milestones exceeding ...

Bio-Thera Solutions has commenced dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC) BAT8006.